1307 related articles for article (PubMed ID: 31651347)
21. Non-coding RNAs in Various Stages of Liver Disease Leading to Hepatocellular Carcinoma: Differential Expression of miRNAs, piRNAs, lncRNAs, circRNAs, and sno/mt-RNAs.
Koduru SV; Leberfinger AN; Kawasawa YI; Mahajan M; Gusani NJ; Sanyal AJ; Ravnic DJ
Sci Rep; 2018 May; 8(1):7967. PubMed ID: 29789629
[TBL] [Abstract][Full Text] [Related]
22. Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma.
Kumar M; Kaur R; Kanthaje S; Dhiman RK; Chakraborti A
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5823-5839. PubMed ID: 36583742
[TBL] [Abstract][Full Text] [Related]
23. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis.
Yu T; Yu J; Lu L; Zhang Y; Zhou Y; Zhou Y; Huang F; Sun L; Guo Z; Hou G; Dong Z; Wang B
Cell Oncol (Dordr); 2021 Aug; 44(4):821-834. PubMed ID: 33974236
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance.
Awan FM; Naz A; Obaid A; Ikram A; Ali A; Ahmad J; Naveed AK; Janjua HA
Sci Rep; 2017 Sep; 7(1):11448. PubMed ID: 28904393
[TBL] [Abstract][Full Text] [Related]
25. Role of microRNAs in the development of hepatocellular carcinoma and acquired drug resistance.
Tricoli L; Niture S; Chimeh U; Kumar D
Front Biosci (Landmark Ed); 2019 Jan; 24(3):545-554. PubMed ID: 30468672
[TBL] [Abstract][Full Text] [Related]
26. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
[TBL] [Abstract][Full Text] [Related]
27. LncRNA NEAT1 promotes autophagy via regulating miR-204/ATG3 and enhanced cell resistance to sorafenib in hepatocellular carcinoma.
Li X; Zhou Y; Yang L; Ma Y; Peng X; Yang S; Li H; Liu J
J Cell Physiol; 2020 Apr; 235(4):3402-3413. PubMed ID: 31549407
[TBL] [Abstract][Full Text] [Related]
28. Single cell RNA-seq analysis identifies a noncoding RNA mediating resistance to sorafenib treatment in HCC.
Zhou K; Nguyen R; Qiao L; George J
Mol Cancer; 2022 Jan; 21(1):6. PubMed ID: 34980140
[No Abstract] [Full Text] [Related]
29. PERK/ATF4-Dependent ZFAS1 Upregulation Is Associated with Sorafenib Resistance in Hepatocellular Carcinoma Cells.
Lin JC; Yang PM; Liu TP
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072570
[TBL] [Abstract][Full Text] [Related]
30. Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: dysregulation and implications for early detection, diagnosis and therapy.
Hou W; Bonkovsky HL
World J Gastroenterol; 2013 Nov; 19(44):7836-45. PubMed ID: 24307777
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive Analysis of the Sorafenib-Associated Druggable Targets on Differential Gene Expression and ceRNA Network in Hepatocellular Carcinoma.
Fu Z; Yang G; Wang T; Gao D; Lin D; Liu X
J Environ Pathol Toxicol Oncol; 2023; 42(4):47-60. PubMed ID: 37522567
[TBL] [Abstract][Full Text] [Related]
32. Long non-coding RNAs as biomarkers and therapeutic targets: Recent insights into hepatocellular carcinoma.
Qiu L; Tang Q; Li G; Chen K
Life Sci; 2017 Dec; 191():273-282. PubMed ID: 28987633
[TBL] [Abstract][Full Text] [Related]
33. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS
Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254
[TBL] [Abstract][Full Text] [Related]
34. Noncoding RNAs in liver cancer stem cells: The big impact of little things.
Lv H; Lv G; Han Q; Yang W; Wang H
Cancer Lett; 2018 Apr; 418():51-63. PubMed ID: 29307614
[TBL] [Abstract][Full Text] [Related]
35. Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma-A Review.
Oura K; Morishita A; Masaki T
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33171811
[TBL] [Abstract][Full Text] [Related]
36. Myc target gene, long intergenic noncoding RNA, Linc00176 in hepatocellular carcinoma regulates cell cycle and cell survival by titrating tumor suppressor microRNAs.
Tran DDH; Kessler C; Niehus SE; Mahnkopf M; Koch A; Tamura T
Oncogene; 2018 Jan; 37(1):75-85. PubMed ID: 28869604
[TBL] [Abstract][Full Text] [Related]
37. Hepatocellular Carcinoma and Nuclear Paraspeckles: Induction in Chemoresistance and Prediction for Poor Survival.
Kessler SM; Hosseini K; Hussein UK; Kim KM; List M; Schultheiß CS; Schulz MH; Laggai S; Jang KY; Kiemer AK
Cell Physiol Biochem; 2019; 52(4):787-801. PubMed ID: 30946555
[TBL] [Abstract][Full Text] [Related]
38. Identification of novel long non-coding RNAs deregulated in hepatocellular carcinoma using RNA-sequencing.
Esposti DD; Hernandez-Vargas H; Voegele C; Fernandez-Jimenez N; Forey N; Bancel B; Le Calvez-Kelm F; McKay J; Merle P; Herceg Z
Oncotarget; 2016 May; 7(22):31862-77. PubMed ID: 26887054
[TBL] [Abstract][Full Text] [Related]
39. Effects of sorafenib on lung metastasis in rats with hepatocellular carcinoma: the role of microRNAs.
Shi Y; Huang A
Tumour Biol; 2015 Nov; 36(11):8455-63. PubMed ID: 26026584
[TBL] [Abstract][Full Text] [Related]
40. Progress and Prospects of Long Noncoding RNAs (lncRNAs) in Hepatocellular Carcinoma.
Li C; Chen J; Zhang K; Feng B; Wang R; Chen L
Cell Physiol Biochem; 2015; 36(2):423-34. PubMed ID: 25968300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
